The information in this section is intended for visitors outside the United States.
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer
Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries
First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study
2013 Annual Review